Movatterモバイル変換

[0]ホーム
URL:

BE2007C038I2 - Use of exendins and agonists thereof for the reduction of food intake - Google Patents

Use of exendins and agonists thereof for the reduction of food intakeDownload PDF

Info

Publication number
BE2007C038I2
BE2007C038I2BE2007C038CBE2007C038CBE2007C038I2BE 2007C038 I2BE2007C038 I2BE 2007C038I2BE 2007C038 CBE2007C038 CBE 2007C038CBE 2007C038 CBE2007C038 CBE 2007C038CBE 2007C038 I2BE2007C038 I2BE 2007C038I2
Authority
BE
Belgium
Prior art keywords
exendins
agonists
reduction
food intake
composition
Prior art date
Application number
BE2007C038C
Other languages
French (fr)
Original Assignee
Amylin Pharmaceuticals Llc
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=27488253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2007C038(I2)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Llc, Astrazeneca Pharmaceuticals LpfiledCriticalAmylin Pharmaceuticals Llc
Publication of BE2007C038I2publicationCriticalpatent/BE2007C038I2/en

Links

Classifications

Landscapes

Abstract

A pharmaceutical composition comprising an exendin or an exendin agonist peptide and a buffer, wherein said composition has a pH of from 3.0 to 8.0, provided that the composition is not suspended in an aqueous buffer at a pH of about 5.6 to 7.4.
BE2007C038C1997-01-072007-05-16Use of exendins and agonists thereof for the reduction of food intakeBE2007C038I2 (en)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US3490597P1997-01-071997-01-07
US5540497P1997-08-081997-08-08
US6602997P1997-11-141997-11-14
US6544297P1997-11-141997-11-14
PCT/US1998/000449WO1998030231A1 (en)1997-01-071998-01-07Use of exendins and agonists thereof for the reduction of food intake

Publications (1)

Publication NumberPublication Date
BE2007C038I2true BE2007C038I2 (en)2018-01-12

Family

ID=27488253

Family Applications (1)

Application NumberTitlePriority DateFiling Date
BE2007C038CBE2007C038I2 (en)1997-01-072007-05-16Use of exendins and agonists thereof for the reduction of food intake

Country Status (15)

CountryLink
US (10)US6956026B2 (en)
EP (2)EP1629849B2 (en)
JP (1)JP4798814B2 (en)
AT (1)ATE304864T1 (en)
AU (1)AU739020B2 (en)
BE (1)BE2007C038I2 (en)
CA (1)CA2277112C (en)
DE (2)DE122007000044I2 (en)
DK (2)DK0996459T3 (en)
ES (2)ES2247676T3 (en)
FR (1)FR07C0031I2 (en)
LU (1)LU91342I2 (en)
NL (1)NL300281I2 (en)
PT (1)PT1629849E (en)
WO (1)WO1998030231A1 (en)

Families Citing this family (214)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
KR100600457B1 (en)*1996-06-052006-07-13로셰 디아그노스틱스 게엠베하 Exendin analogs, preparation methods thereof, and pharmaceuticals containing the same
ES2359031T3 (en)1996-08-082011-05-17Amylin Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITION THAT INCLUDES AN EXENDIN-4 PEPTIDE.
WO1998020895A1 (en)*1996-11-121998-05-22Novo Nordisk A/SUse of glp-1 peptides
AU739020B2 (en)1997-01-072001-10-04Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the reduction of food intake
US20040022807A1 (en)*1998-06-052004-02-05Duft Bradford JMethods for treating obesity
US7910548B2 (en)*1997-06-062011-03-22Amylin Pharmaceuticals, Inc.Methods for treating obesity
NZ502592A (en)*1997-08-082002-03-28Amylin Pharmaceuticals IncExendin agonist peptides and their use in the treatment of type I and II diabetes
EP1938831A1 (en)*1997-08-082008-07-02Amylin Pharmaceuticals, Inc.Novel exendin agonist compounds
US7157555B1 (en)1997-08-082007-01-02Amylin Pharmaceuticals, Inc.Exendin agonist compounds
EP1941900A1 (en)*1997-11-142008-07-09Amylin Pharmaceuticals, Inc.Novel exendin agonist compounds
US7223725B1 (en)1997-11-142007-05-29Amylin Pharmaceuticals, Inc.Exendin agonist compounds
JP2003522721A (en)*1997-11-142003-07-29アミリン・ファーマシューティカルズ，インコーポレイテッド New exendin agonist compounds
AU2006225176B2 (en)*1997-11-142009-01-08Amylin Pharmaceuticals, LlcNovel exendin agonist compounds
AU2003200129B2 (en)*1997-11-142006-06-22Amylin Pharmaceuticals, LlcNovel Exendin Agonist Compounds
EP1938830A1 (en)*1997-11-142008-07-02Amylin Pharmaceuticals, Inc.Novel exendin agonist compounds
ATE383867T1 (en)*1997-11-142008-02-15Amylin Pharmaceuticals Inc NOVEL EXENDIN AGONISTS
US7220721B1 (en)1997-11-142007-05-22Amylin Pharmaceuticals, Inc.Exendin agonist peptides
US6998387B1 (en)*1998-03-192006-02-14Amylin Pharmaceuticals, Inc.Human appetite control by glucagon-like peptide receptor binding compounds
US6429197B1 (en)1998-10-082002-08-06Bionebraska, Inc.Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en)1999-04-302007-08-21Amylin Pharmaceuticals, Inc.Compositions and methods for treating peripheral vascular disease
US6284725B1 (en)*1998-10-082001-09-04Bionebraska, Inc.Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
DE60044041D1 (en)*1999-01-142010-04-29Amylin Pharmaceuticals Inc Exendine for glucagon suppression
US7399489B2 (en)1999-01-142008-07-15Amylin Pharmaceuticals, Inc.Exendin analog formulations
US20030087820A1 (en)*1999-01-142003-05-08Young Andrew A.Novel exendin agonist formulations and methods of administration thereof
BRPI0007820B8 (en)1999-01-142021-05-25Amylin Pharmaceuticals Llc exendin agonist pharmaceutical formulations and their uses
US20050272652A1 (en)1999-03-292005-12-08Gault Victor APeptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2000066629A1 (en)1999-04-302000-11-09Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonists
US6924264B1 (en)1999-04-302005-08-02Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonists
US20090175821A1 (en)*1999-05-172009-07-09Bridon Dominique PModified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en)*1999-10-152003-02-04Conjuchem, Inc.Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en)1999-06-012003-01-14Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en)1999-07-122003-03-04Zealand Pharma A/SPeptide agonists of GLP-1 activity
EP1076066A1 (en)*1999-07-122001-02-14Zealand Pharmaceuticals A/SPeptides for lowering blood glucose levels
EP1246638B2 (en)*2000-01-102014-07-30Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
JP2003525908A (en)*2000-03-082003-09-02ノボ ノルディスク アクティーゼルスカブ Low serum lipids
CN1568195B (en)2000-12-142011-03-02安米林药品公司Peptide YY and peptide YY agonists for treatment of metabolic disorders
US20090281032A1 (en)*2001-03-012009-11-12Peter Raymond FlattModified CCK peptides
ATE408414T1 (en)2001-07-312008-10-15Us Gov Health & Human Serv GLP 1 EXENDIN 4 PEPTIDE ANALOGUES AND THEIR USES
GB0121709D0 (en)*2001-09-072001-10-31Imp College Innovations LtdFood inhibition agent
ATE419863T1 (en)*2001-09-242009-01-15Imp Innovations Ltd PYY3-36 FOR REDUCING OR PREVENTING OBESITY
EP1461069A2 (en)*2001-12-292004-09-29Novo Nordisk A/SCombined use of a glp-1 compound and another drug for treating dyslipidemia
EP1474164B1 (en)*2002-01-082008-10-29Amylin Pharmaceuticals, Inc.Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
AU2003201998C1 (en)*2002-01-102012-10-25Imperial Innovations LimitedModification of feeding behavior
US8058233B2 (en)*2002-01-102011-11-15Oregon Health And Science UniversityModification of feeding behavior using PYY and GLP-1
US7105489B2 (en)*2002-01-222006-09-12Amylin Pharmaceuticals, Inc.Methods and compositions for treating polycystic ovary syndrome
EP2028192A1 (en)2002-07-042009-02-25Zealand Pharma A/SGLP-1 and methods for treating diabetes
KR20050083713A (en)2002-10-022005-08-26질랜드 파마 에이/에스Stabilized exendin-4 compounds
AU2003286472A1 (en)*2002-10-172004-05-04Alkermes Controlled Therapeutics, Inc. IiMicroencapsulation and sustained release of biologically active polypeptides
BR0315523A (en)*2002-10-222005-08-30Waratah Pharmaceuticals Inc Diabetes treatment
AU2003283216A1 (en)*2002-12-032004-06-23Novo Nordisk A/SCombination treatment using exendin-4 and thiazolidinediones
EP1581247A4 (en)*2002-12-112007-09-12Amylin Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR TREATING STONE LEVENTHAL SYNDROME
US7790681B2 (en)*2002-12-172010-09-07Amylin Pharmaceuticals, Inc.Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en)*2002-12-192004-10-21Alain BaronCompositions for the treatment and prevention of nephropathy
US7731947B2 (en)2003-11-172010-06-08Intarcia Therapeutics, Inc.Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en)*2003-01-102003-02-12Imp College Innovations LtdModification of feeding behaviour
WO2005000222A2 (en)*2003-05-302005-01-06Amylin Pharmaceuticals, Inc.Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP1663289A2 (en)*2003-08-292006-06-07Amylin Pharmaceuticals, Inc.Methods for treating or ameliorating ghrelin-associated diseases and disorders
US20060287221A1 (en)2003-11-132006-12-21Novo Nordisk A/SSoluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
US8263084B2 (en)*2003-11-132012-09-11Hanmi Science Co., LtdPharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (en)2007-11-292012-04-24한미사이언스 주식회사A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
ES2373660T3 (en)*2003-11-132012-02-07Novo Nordisk A/S PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INSULINOTROPIC GLP-1 ANALOG (7-37), ASP INSULIN (B28) AND A TENSIOACTIVE.
AU2004290862B2 (en)2003-11-202010-06-03Novo Nordisk A/SPropylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2005056036A2 (en)*2003-12-092005-06-23Novo Nordisk A/SRegulation of food preference using glp-1 agonists
US8076288B2 (en)2004-02-112011-12-13Amylin Pharmaceuticals, Inc.Hybrid polypeptides having glucose lowering activity
NZ549332A (en)2004-02-112008-11-28Amylin Pharmaceuticals IncAmylin family peptides and methods for making and using them
EP2422806A3 (en)*2004-02-112012-06-13Amylin Pharmaceuticals Inc.Hybrid polypeptides with selectable properties
PT2100904E (en)*2004-04-232010-09-24Conjuchem Biotechnologies IncSolid phase for use in a method for the purification of albumin conjugates
US20090069226A1 (en)*2004-05-282009-03-12Amylin Pharmaceuticals, Inc.Transmucosal delivery of peptides and proteins
WO2005120492A1 (en)*2004-06-112005-12-22Novo Nordisk A/SCounteracting drug-induced obesity using glp-1 agonists
WO2006052608A2 (en)2004-11-012006-05-18Amylin Pharmaceuticals, Inc.Treatment of obesity and related disorders
AU2005305036B2 (en)*2004-11-012011-03-10Amylin Pharmaceuticals, LlcTreatment of obesity and related disorders
US8394765B2 (en)2004-11-012013-03-12Amylin Pharmaceuticals LlcMethods of treating obesity with two different anti-obesity agents
WO2006074051A2 (en)*2004-12-302006-07-13Diakine Therapeutics, Inc.PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
WO2006083761A2 (en)2005-02-032006-08-10Alza CorporationSolvent/polymer solutions as suspension vehicles
US11246913B2 (en)2005-02-032022-02-15Intarcia Therapeutics, Inc.Suspension formulation comprising an insulinotropic peptide
US8263545B2 (en)2005-02-112012-09-11Amylin Pharmaceuticals, Inc.GIP analog and hybrid polypeptides with selectable properties
KR20070115947A (en)2005-02-112007-12-06아밀린 파마슈티칼스, 인크. JP analogs and hybrid polypeptides with selectable properties
NZ561400A (en)*2005-03-112010-02-26Endo Pharmaceuticals SolutionsControlled release formulations of octreotide
US7759312B2 (en)*2005-03-112010-07-20Endo Pharmaceuticals Solutions Inc.Delivery of dry formulations of octreotide
EP2248527A3 (en)*2005-03-312013-04-03Amylin Pharmaceuticals, LLCCompositions and methods for the control, prevention, and treatment of obesity and eating disorders
GB0511986D0 (en)*2005-06-132005-07-20Imp College Innovations LtdNovel compounds and their effects on feeding behaviour
EP2330124B1 (en)*2005-08-112015-02-25Amylin Pharmaceuticals, LLCHybrid polypeptides with selectable properties
PT2347762T (en)2005-08-192019-06-17Amylin Pharmaceuticals LlcExendin for treating diabetes and reducing body weight
WO2007022518A2 (en)*2005-08-192007-02-22Amylin Pharmaceuticals, Inc.New uses of glucoregulatory proteins
JP2009512715A (en)2005-10-212009-03-26ノバルティス アクチエンゲゼルシャフト Combination of renin inhibitor and anti-dyslipidemic agent and / or anti-obesity agent
WO2007055743A2 (en)*2005-11-012007-05-18Amylin Pharmaceuticals, Inc.Treatment of obesity and related disorders
AU2006312307A1 (en)*2005-11-012007-05-18Amylin Pharmaceuticals, Inc.Treatment of obesity and related disorders
US8039432B2 (en)*2005-11-092011-10-18Conjuchem, LlcMethod of treatment of diabetes and/or obesity with reduced nausea side effect
US8147938B2 (en)*2005-11-292012-04-03Kolon Industries, Inc.Braid-reinforced composite hollow fiber membrane
JP2009520469A (en)*2005-12-222009-05-28コンジュクヘム ビオテクフノロギエス インコーポレイテッド Method for the production of preformed conjugates of albumin and therapeutic agents
KR20090031368A (en)*2006-05-262009-03-25아밀린 파마슈티칼스, 인크. Compositions and methods for treating congestive heart failure
MX2008014870A (en)2006-05-302009-02-12Intarcia Therapeutics IncTwo-piece, internal-channel osmotic delivery system flow modulator.
ES2371495T3 (en)*2006-07-242012-01-03Biorexis Pharmaceutical Corporation EXENDINE FUSION PROTEINS.
EP2068910A2 (en)*2006-08-042009-06-17Amylin Pharmaceuticals, Inc.Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
US8501693B2 (en)*2006-08-042013-08-06Amylin Pharmaceuticals, LlcUse of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
EP3421031A1 (en)2006-08-092019-01-02Intarcia Therapeutics, IncOsmotic delivery systems and piston assemblies
US8497240B2 (en)2006-08-172013-07-30Amylin Pharmaceuticals, LlcDPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008022267A2 (en)*2006-08-172008-02-21Wellstat Therapeutics CorporationCombination treatment for metabolic disorders
US20090318353A1 (en)*2006-08-252009-12-24Novo Nordisk A/SAcylated Exendin-4 Compounds
KR100872304B1 (en)*2006-11-282008-12-05주식회사 코오롱 Composite hollow fiber membrane reinforced with knitting
TWI428346B (en)*2006-12-132014-03-01Imp Innovations LtdNovel compounds and their effects on feeding behaviour
RU2413528C2 (en)2007-01-182011-03-10Открытое Акционерное Общество "Валента Фармацевтика"Exenatide and dalargin drug for treating diabetes, adminisration and therapy
MX2009011123A (en)2007-04-232009-11-02Intarcia Therapeutics IncSuspension formulations of insulinotropic peptides and uses thereof.
JP2009019027A (en)2007-07-162009-01-29Hanmi Pharmaceutical Co Ltd Insulin-secreting peptide derivatives with amino-terminal amino acid mutations
CA2705708A1 (en)*2007-11-142009-05-22Amylin Pharmaceuticals, Inc.Methods for treating obesity and obesity related diseases and disorders
WO2009075859A2 (en)*2007-12-112009-06-18Conjuchem Biotechnologies Inc.Formulation of insulinotropic peptide conjugates
WO2009102467A2 (en)2008-02-132009-08-20Intarcia Therapeutics, Inc.Devices, formulations, and methods for delivery of multiple beneficial agents
US20110046071A1 (en)*2008-03-052011-02-24Tel Hashomer Medical Research Infrastructure And Services Ltd.GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer
EP2303313B1 (en)2008-05-212015-10-28Amylin Pharmaceuticals, LLCExendins to lower cholestrol and triglycerides
US8071537B2 (en)2008-06-252011-12-06Endo Pharmaceuticals Solutions Inc.Implantable device for the sustained release of a polypeptide
KR20110025974A (en)*2008-06-252011-03-14엔도 파마슈티컬즈, 솔루션스 아이엔씨. Octreotide Implants Containing Release Agents
WO2010010555A2 (en)*2008-07-212010-01-28Transpharma Medical Ltd.Transdermal system for extended delivery of incretins and incretin mimetic peptides
CN104248623B (en)2008-09-042020-04-03安米林药品有限责任公司 Sustained release formulations using non-aqueous carriers
DE102008051834A1 (en)2008-10-172010-04-22Sanofi-Aventis Deutschland GmbhDrug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
CR20170369A (en)2008-10-172017-11-01Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST (Divisional 2011-0188)
DE102009038210A1 (en)2009-08-202011-03-03Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
DE102008053048A1 (en)2008-10-242010-04-29Sanofi-Aventis Deutschland GmbhMedicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
US9238878B2 (en)*2009-02-172016-01-19Redwood Bioscience, Inc.Aldehyde-tagged protein-based drug carriers and methods of use
CN101870728A (en)2009-04-232010-10-27派格生物医药(苏州)有限公司Novel Exendin variant and conjugate thereof
US20120231022A1 (en)2009-05-282012-09-13Amylin Pharmaceuticals, Inc.Glp-1 receptor agonist compounds for sleep enhancement
NZ598686A (en)2009-09-282014-05-30Intarcia Therapeutics IncRapid establishment and/or termination of substantial steady-state drug delivery
WO2011056713A2 (en)*2009-11-032011-05-12Amylin Pharmaceuticals, Inc.Glp-1 receptor agonist compounds for obstructive sleep apnea
PL2498802T3 (en)2009-11-132015-06-30Sanofi Aventis DeutschlandPharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
DE102010011919A1 (en)2010-03-182011-09-22Sanofi-Aventis Deutschland GmbhLiquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine
WO2011058082A1 (en)2009-11-132011-05-19Sanofi-Aventis Deutschland GmbhPharmaceutical composition comprising a glp-1 agonist and methionine
WO2011064316A2 (en)2009-11-252011-06-03Paolo BottiMucosal delivery of peptides
CN102100912B (en)*2009-12-162015-04-22上海蓝心医药科技有限公司Administration composition and preparation method and using method thereof
EP2555791B1 (en)2010-04-092017-11-01Sinai Health SystemMethods for treating disorders of the gastrointestinal tract using a glp-1 agonist
EA023925B1 (en)2010-04-272016-07-29Зилэнд Фарма А/СPeptide conjugates of glp-1 receptor agonists and their use
WO2012027331A1 (en)2010-08-272012-03-01Ironwood Pharmaceuticals, Inc.Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
SG187904A1 (en)2010-08-302013-04-30Sanofi Aventis DeutschlandUse of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9616097B2 (en)2010-09-152017-04-11Synergy Pharmaceuticals, Inc.Formulations of guanylate cyclase C agonists and methods of use
EA201390450A1 (en)2010-09-282013-07-30Амилин Фармасьютикалс, Ллк. POLYPEPTIDES WITH INCREASED DURATION OF ACTION
EP2654767A4 (en)2010-12-222014-05-21Amylin Pharmaceuticals Inc GLP-1 RECEPTOR AGONISTS FOR TRANSPLANTATION OF ISLET CELLS
BR112013017980A2 (en)2011-01-142017-06-27Redwood Bioscience Inc aldehyde-labeled immunoglobulin polypeptides and method of use
US20120208755A1 (en)2011-02-162012-08-16Intarcia Therapeutics, Inc.Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN108676076A (en)2011-03-012018-10-19辛纳吉制药公司The method for preparing guanosine cyclic mono-phosphate agonist
US9821032B2 (en)2011-05-132017-11-21Sanofi-Aventis Deutschland GmbhPharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP2014521594A (en)2011-05-252014-08-28アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Long duration dual hormone conjugate
EP2713722B1 (en)2011-05-312017-03-15Receptos, LLCNovel glp-1 receptor stabilizers and modulators
JP6396211B2 (en)2011-07-042018-09-26インペリアル・イノベイションズ・リミテッド New compounds and their effects on feeding behavior
CN104271588B (en)2011-07-082017-10-10安米林药品有限责任公司 Engineered polypeptides with enhanced duration of action and reduced immunogenicity
EP2750699B1 (en)2011-08-292015-07-22Sanofi-Aventis Deutschland GmbHPharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en)2011-09-012016-12-01Sanofi Aventis DeutschlandPharmaceutical composition for use in the treatment of a neurodegenerative disease
SI2763690T1 (en)2011-10-042016-03-31Sanofi-Aventis Deutschland GmbhLixisenatide for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
EP2763691A1 (en)2011-10-042014-08-13Sanofi-Aventis Deutschland GmbHGlp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
WO2013064669A1 (en)2011-11-032013-05-10Zealand Pharma A/SGlp-1 receptor agonist peptide gastrin conjugates
MX365923B (en)2011-12-122019-06-20Celgene Int Ii SarlCarboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes.
WO2013186240A2 (en)2012-06-142013-12-19SanofiExendin-4 peptide analogues
EP2875043B1 (en)2012-07-232016-12-21Zealand Pharma A/SGlucagon analogues
TWI608013B (en)2012-09-172017-12-11西蘭製藥公司 Glucagon analog
UA116217C2 (en)2012-10-092018-02-26СанофіExendin-4 derivatives as dual glp1/glucagon agonists
MX360317B (en)2012-12-212018-10-29Sanofi SaFunctionalized exendin-4 derivatives.
KR101581497B1 (en)2013-01-242015-12-30강원대학교산학협력단Pharmaceutical composition for the prevention and treatment of parkinson's disease and alzheimer's disease containing ginseng fructus extract
TWI641381B (en)2013-02-042018-11-21法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogs and/or insulin derivatives
SI2968471T1 (en)2013-03-012017-11-30Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaPeptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
AU2014274812B2 (en)2013-06-052018-09-27Bausch Health Ireland LimitedUltra-pure agonists of guanylate cyclase C, method of making and using same
KR102271179B1 (en)2013-06-112021-07-01셀진 인터내셔널 Ii 에스에이알엘Novel glp-1 receptor modulators
US9988429B2 (en)2013-10-172018-06-05Zealand Pharma A/SGlucagon analogues
AU2014336098B2 (en)2013-10-172018-05-10Boehringer Ingelheim International GmbhAcylated glucagon analogues
CA2928526A1 (en)2013-11-012015-05-07Spherium Biomed S.L.Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
WO2015067716A1 (en)2013-11-062015-05-14Zealand Pharma A/SGlucagon-glp-1-gip triple agonist compounds
WO2015067715A2 (en)2013-11-062015-05-14Zealand Pharma A/SGip-glp-1 dual agonist compounds and methods
EP3080149A1 (en)2013-12-132016-10-19SanofiDual glp-1/glucagon receptor agonists
WO2015086728A1 (en)2013-12-132015-06-18SanofiExendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en)2013-12-132015-06-18SanofiDual glp-1/gip receptor agonists
EP3080152A1 (en)2013-12-132016-10-19SanofiNon-acylated exendin-4 peptide analogues
CN105899191B (en)2014-01-092020-06-16赛诺菲Stabilized glycerol-free pharmaceutical formulations of insulin analogues and/or insulin derivatives
MX2016008977A (en)2014-01-092016-10-04Sanofi SaStabilized pharmaceutical formulations of insulin aspart.
JP6641280B2 (en)2014-01-092020-02-05サノフイＳａｎｏｆｉ Stabilized pharmaceutical formulations of insulin analogues and / or insulin derivatives
TW201625670A (en)2014-04-072016-07-16賽諾菲公司Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en)2014-04-072016-07-16賽諾菲公司Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en)2014-04-072016-07-16賽諾菲公司Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en)2014-06-182018-04-03SanofiExendin-4 derivatives as selective glucagon receptor agonists
AU2015292356B2 (en)2014-07-252020-02-06Receptos LlcNovel GLP-1 receptor modulators
RU2573933C1 (en)2014-08-212016-01-27Дафот Энтерпрайсис ЛимитедPeptide for medical treatment of pancreatic diabetes of 2nd type and its complications
US9708272B2 (en)2014-08-292017-07-18Tes Pharma S.R.L.Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US9889085B1 (en)2014-09-302018-02-13Intarcia Therapeutics, Inc.Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3212218B1 (en)2014-10-292021-06-30Zealand Pharma A/SGip agonist compounds and methods
WO2016094729A1 (en)2014-12-102016-06-16Celgene International Ii SarlGlp-1 receptor modulators
EP3229828B1 (en)2014-12-122023-04-05Sanofi-Aventis Deutschland GmbHInsulin glargine/lixisenatide fixed ratio formulation
EP3267994A4 (en)2015-03-092018-10-31Intekrin Therapeutics, Inc.Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
TWI748945B (en)2015-03-132021-12-11德商賽諾菲阿凡提斯德意志有限公司Treatment type 2 diabetes mellitus patients
TW201705975A (en)2015-03-182017-02-16賽諾菲阿凡提斯德意志有限公司Treatment of type 2 diabetes mellitus patients
US10336802B2 (en)2015-04-162019-07-02Zealand Pharma A/SAcylated glucagon analogue
SI3297653T1 (en)2015-05-222022-01-31The Board Of Trustees Of Leland Stanford Junior UniversityTreatment of post-bariatric hypoglycemia with glp-1 antagonists
AU2016270984B2 (en)2015-06-032021-02-25Intarcia Therapeutics, Inc.Implant placement and removal systems
AR105319A1 (en)2015-06-052017-09-27Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en)2015-07-102017-02-16賽諾菲公司New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
CN108138563B (en)*2015-10-012021-09-21斯伦贝谢技术有限公司Active damping for NMR logging tools
SG11201802777XA (en)2015-10-142018-05-30X Therma IncCompositions and methods for reducing ice crystal formation
UA127495C2 (en)2015-12-232023-09-13Амджен Інк. ISOLATED ANTIGEN-BINDING PROTEIN THAT SPECIFICALLY BINDS TO HUMAN GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
WO2017152014A1 (en)2016-03-042017-09-08Eiger Biopharmaceuticals, Inc.Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2017181007A1 (en)*2016-04-152017-10-19Robert DoylePeptide drug improvement using vitamin b12 and haptocorrin binding substrate conjugates
CA3019398A1 (en)2016-04-262017-11-02R.P. Scherer Technologies, LlcAntibody conjugates and methods of making and using the same
JP7077237B2 (en)2016-05-162022-05-30インターシア セラピューティクス，インコーポレイティド Glucagon Receptor Selective Polypeptides and Their Usage
USD860451S1 (en)2016-06-022019-09-17Intarcia Therapeutics, Inc.Implant removal tool
USD840030S1 (en)2016-06-022019-02-05Intarcia Therapeutics, Inc.Implant placement guide
EP3515408A1 (en)2016-09-232019-07-31Delpor, Inc.Stable compositions for incretin mimetic compounds
CN109952292A (en)2016-10-142019-06-28Tes制药有限责任公司 Inhibitors of α-amino-β-carboxyhexadienedioic acid semialdehyde decarboxylase
FI3541366T3 (en)2016-11-212025-03-06Amylyx Pharmaceuticals Inc BUFFERED FORMULATIONS OF EXENDIN (9-39)
US11285180B2 (en)2016-12-062022-03-29Inserm (Institut National De La Sante Et De La Recherche Medicale)Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
WO2018104561A1 (en)2016-12-092018-06-14Zealand Pharma A/SAcylated glp-1/glp-2 dual agonists
MX2019008006A (en)2017-01-032019-08-29Intarcia Therapeutics Inc METHODS INCLUDING THE CONTINUOUS ADMINISTRATION OF A GLP-1 RECEPTOR AGONIST AND THE CO-ADMINISTRATION OF A DRUG.
JOP20190177A1 (en)2017-01-172019-07-16Amgen IncMethod of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
MX2019011867A (en)2017-04-032020-01-09Coherus Biosciences IncPparî³ agonist for treatment of progressive supranuclear palsy.
CA3062194A1 (en)2017-06-202018-12-27Amgen Inc.Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
RS65380B1 (en)2017-08-242024-04-30Novo Nordisk AsGlp-1 compositions and uses thereof
WO2019197466A1 (en)2018-04-102019-10-17Sanofi-Aventis Deutschland GmbhMethod for cleavage of solid phase-bound peptides from the solid phase
SG11202010016QA (en)2018-04-102020-11-27Sanofi Aventis DeutschlandLixisenatide synthesis with capping
BR112021009589A2 (en)2018-11-202021-08-17Tes Pharma S.R.L. alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
US20220152154A1 (en)2019-03-082022-05-19Amgen Inc.Growth differentiation factor 15 combination therapy
IL294520A (en)2020-02-182022-09-01Novo Nordisk As Pharmaceutical formulations
WO2024123812A1 (en)2022-12-052024-06-13Shattuck Labs, Inc.Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5120712A (en)*1986-05-051992-06-09The General Hospital CorporationInsulinotropic hormone
US5118666A (en)*1986-05-051992-06-02The General Hospital CorporationInsulinotropic hormone
US5175145A (en)1988-08-261992-12-29Amylin Pharmaceuticals, Inc.Treatment of diabetes mellitus with amylin agonists
ATE193541T1 (en)1989-03-202000-06-15Gen Hospital Corp INSULINOTROPIC HORMONE
JP3262329B2 (en)1990-01-242002-03-04アイ． バックレイ，ダグラス GLP-1 analog useful for the treatment of diabetes
US5545618A (en)*1990-01-241996-08-13Buckley; Douglas I.GLP-1 analogs useful for diabetes treatment
US5187154A (en)*1990-12-131993-02-16Board Of Regents, The University Of Texas SystemDiagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en)*1991-03-151993-11-23Amylin Pharmaceuticals, Inc.Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (en)1991-03-082003-05-28Amylin Pharmaceuticals Inc.Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
DK36392D0 (en)1992-03-191992-03-19Novo Nordisk As USE OF CHEMICAL COMPOUND
PL176007B1 (en)1992-06-151999-03-31Scios IncNovel derivatives of polypeptide glp-1
US5424286A (en)*1993-05-241995-06-13Eng; JohnExendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424289A (en)*1993-07-301995-06-13Alza CorporationSolid formulations of therapeutic proteins for gastrointestinal delivery
BR9407424A (en)1993-09-071996-04-09Amylin Pharmaceuticals Inc Methods to regulate gastrointestinal motility
NZ273258A (en)1993-09-092000-01-28Lorus Therapeutics IncImmunomodulator composition with components less than 3000 D that are extractable from bile, stimulate monocytes and macrophages and modulate TNF
US5705483A (en)1993-12-091998-01-06Eli Lilly And CompanyGlucagon-like insulinotropic peptides, compositions and methods
JPH10511077A (en)*1994-08-261998-10-27ナンシー、 エム． リー、 Analgesic method using dynorphin analog cleaved at N-terminal group
US5574008A (en)1994-08-301996-11-12Eli Lilly And CompanyBiologically active fragments of glucagon-like insulinotropic peptide
US5641425A (en)*1994-09-081997-06-24Multiform Desiccants, Inc.Oxygen absorbing composition
US5512549A (en)*1994-10-181996-04-30Eli Lilly And CompanyGlucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5739106A (en)*1995-06-071998-04-14Rink; Timothy J.Appetite regulating compositions
CA2225454A1 (en)*1995-06-301997-01-23Thomas Wesley StephensMethods for treating diabetes
SE504450C2 (en)1996-02-191997-02-17Kavlugnt Ab Coupling device for connecting a working tool to a working machine; both mechanical coupling and quick coupling of the hydraulic couplings
KR100600457B1 (en)1996-06-052006-07-13로셰 디아그노스틱스 게엠베하 Exendin analogs, preparation methods thereof, and pharmaceuticals containing the same
US5686511A (en)*1996-06-281997-11-11The Valspar CorporationEsterifying epoxy resin with carboxyl polymer and quenching
AU4050797A (en)1996-08-021998-02-25Ligand Pharmaceuticals IncorporatedPrevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
ES2359031T3 (en)*1996-08-082011-05-17Amylin Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITION THAT INCLUDES AN EXENDIN-4 PEPTIDE.
UA65549C2 (en)*1996-11-052004-04-15Елі Ліллі Енд КомпаніUse of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
US5677279A (en)*1996-12-161997-10-14Amylin Pharmaceuticals, Inc.Methods and compositions for treating pain with amylin or agonists thereof
AU739020B2 (en)*1997-01-072001-10-04Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the reduction of food intake
US5830904A (en)*1997-02-051998-11-03University Of Kentucky Research FoundationLobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5846937A (en)1997-03-031998-12-081149336 Ontario Inc.Method of using exendin and GLP-1 to affect the central nervous system
US7910548B2 (en)*1997-06-062011-03-22Amylin Pharmaceuticals, Inc.Methods for treating obesity
NZ502592A (en)1997-08-082002-03-28Amylin Pharmaceuticals IncExendin agonist peptides and their use in the treatment of type I and II diabetes
AU1306099A (en)1997-12-121999-07-05Warner-Lambert CompanyAntihyperlipidemic statin-lp(a) inhibitor combinations
US6187777B1 (en)*1998-02-062001-02-13Amgen Inc.Compounds and methods which modulate feeding behavior and related diseases
SE9801992D0 (en)1998-06-041998-06-04Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6783942B2 (en)*1998-10-082004-08-31Uab Research FoundationIsolated polynucleotide associated with type II diabetes mellitus and methods of use thereof
US6326396B1 (en)*1998-11-202001-12-04Alteon, Inc.Glucose and lipid lowering compounds
BRPI0007820B8 (en)*1999-01-142021-05-25Amylin Pharmaceuticals Llc exendin agonist pharmaceutical formulations and their uses
US6153432A (en)*1999-01-292000-11-28Zen-Bio, IncMethods for the differentiation of human preadipocytes into adipocytes
US6924264B1 (en)*1999-04-302005-08-02Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonists
WO2000066629A1 (en)1999-04-302000-11-09Amylin Pharmaceuticals, Inc.Modified exendins and exendin agonists
US6506724B1 (en)*1999-06-012003-01-14Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
EP1246638B2 (en)*2000-01-102014-07-30Amylin Pharmaceuticals, Inc.Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
US6608038B2 (en)*2000-03-152003-08-19Novartis AgMethods and compositions for treatment of diabetes and related conditions via gene therapy
US7232798B2 (en)*2001-11-132007-06-19Tran Loi HNeuroprotection and neuroegenisis by administering cyclic prolyl glycine
US7105489B2 (en)*2002-01-222006-09-12Amylin Pharmaceuticals, Inc.Methods and compositions for treating polycystic ovary syndrome

Also Published As

Publication numberPublication date
ES2247676T3 (en)2006-03-01
DE122007000044I1 (en)2011-02-10
NL300281I1 (en)2007-09-03
DE69831673D1 (en)2005-10-27
PT1629849E (en)2013-07-09
US20050059601A1 (en)2005-03-17
FR07C0031I2 (en)2019-06-21
EP0996459A4 (en)2002-04-10
US7700549B2 (en)2010-04-20
US7297761B2 (en)2007-11-20
LU91342I2 (en)2007-12-06
DE122007000044I2 (en)2011-05-05
JP2002508742A (en)2002-03-19
DE69831673C5 (en)2015-01-22
AU739020B2 (en)2001-10-04
US20050043238A1 (en)2005-02-24
US20110034377A1 (en)2011-02-10
US6956026B2 (en)2005-10-18
FR07C0031I1 (en)2007-06-22
US7419952B2 (en)2008-09-02
US20050101537A1 (en)2005-05-12
US6989366B2 (en)2006-01-24
ATE304864T1 (en)2005-10-15
US7115569B2 (en)2006-10-03
LU91342I9 (en)2018-12-31
EP0996459B1 (en)2005-09-21
CA2277112A1 (en)1998-07-16
US7741269B2 (en)2010-06-22
EP0996459A1 (en)2000-05-03
US20090176704A1 (en)2009-07-09
EP1629849B1 (en)2013-05-22
CA2277112C (en)2008-08-26
DK1629849T3 (en)2013-08-12
EP1629849A2 (en)2006-03-01
US20060148713A1 (en)2006-07-06
EP1629849A3 (en)2006-04-26
US8288338B2 (en)2012-10-16
HK1025252A1 (en)2000-11-10
US20130023470A1 (en)2013-01-24
NL300281I2 (en)2018-01-23
ES2425559T3 (en)2013-10-16
EP1629849B2 (en)2017-10-04
DK1629849T4 (en)2017-12-04
JP4798814B2 (en)2011-10-19
DK0996459T3 (en)2006-01-16
US7138375B2 (en)2006-11-21
US20020137666A1 (en)2002-09-26
AU6239498A (en)1998-08-03
WO1998030231A1 (en)1998-07-16
US20030087821A1 (en)2003-05-08
ES2425559T5 (en)2018-02-02
US20050215469A1 (en)2005-09-29
DE69831673T2 (en)2006-06-22

Similar Documents

PublicationPublication DateTitle
BE2007C038I2 (en)Use of exendins and agonists thereof for the reduction of food intake
IL133220A0 (en)Stabilized antibody formulation
EP2270147A3 (en)Method for controlling the activity of immunologically functional molecule
EP0852946A3 (en)Composition for cosmetic, pharmaceutical or dietetic use based on an amino-sugar and/or a polyhydroxylic acid
MY132812A (en)Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
EP0906310A4 (en)OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
HUP0001758A3 (en)Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the c-terminus, pharmaceutical compositions comprising thereof and their use
AU2764797A (en)Somatostatin agonists and antagonists
ZW17893A1 (en)Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof.
HUP9701437A3 (en)Use of complex lipides as stabilizing additives in pharmaceutical compositions containing digestive enzymes, pharmaceutical compns. and kits
HUP0105313A3 (en)Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
PL366851A1 (en)Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
EP0791601A3 (en)An agent promoting bone formation and inhibiting bone resorption
CA2338794A1 (en)New oral formulation for 5-ht4 agonists or antagonists
WO1997028104A3 (en)Buffer systems for use in stabilizing pharmaceutical preparations
AU2670495A (en)Ifn-beta liquid formulations
AU4178497A (en)HTm4, methods of treatment and assays, agonists and antagonists
HUP0105111A3 (en)2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same
ZA9710254B (en)LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
AU2002221772A1 (en)Derivatives of the human macrophage-migration inhibition factor (mif) and use thereof in pharmaceutical preparations in screening methods or the identification of analogues, agonists and antagonists
CA2247998A1 (en)Fragments of cr1 and their use
孙绪生 et al.EskoLansimies
YamauchiStudies on host defense effects of bovine lactoferrin and its utilization as functional food materials
AU5497698A (en)Method for stabilizing peptide and peptide-containing lyophilized pharmaceutical composition using the method
NO20021857D0 (en) 5-Halo-4-fluoro-4,7,7-trimethyl-3-oxabicyclo [4.1.0] heptan-2-one, its preparation and its use in the preparation of cyclopropanecarboxylic acids
[8]ページ先頭
©2009-2025 Movatter.jp